Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.

LA, Emens; L, Molinero; S, Loi; HS, Rugo; A, Schneeweiss; V, Diéras; H, Iwata; CH, Barrios; M, Nechaeva; A, Nguyen-Duc; SY, Chui; A, Husain; EP, Winer; S, Adams; P, Schmid

doi:10.1093/jnci/djab004

Public

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.

Shared by NobleBlocks on Aug 1, 2021 • 12:00 AM UTC

Authors:

Emens LA

Molinero L

Loi S

Abstract

<h4>Background</h4>Understanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors may help optimize both patient and treatment selection in metastatic triple-negative breast cancer. In this substudy f...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!